After hypertension competitor gets bought, Mineralys lines up IPO plans
Mineralys Therapeutics has penciled in a $100 million initial public offering to take its investigational hypertension drug into Phase III testing.
The Philadelphia startup released topline results for its hypertension drug, dubbed MLS-101 or lorundrostat, two months ago, saying it met the primary endpoint of reducing systolic blood pressure for patients who were on at least two background medicines.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.